The Supreme Court of the United States on Thursday temporarily preserved nationwide access to the abortion pill mifepristone through telemedicine and mail delivery, restoring a 2023 federal rule issued by the U.S. Food and Drug Administration during former President Joe Biden’s administration. The unsigned order lifted a lower court ruling backed by Republican-led Louisiana that would have reinstated mandatory in-person visits for obtaining the medication. Conservative Justices Samuel Alito and Clarence Thomas dissented.
The legal dispute centers on mifepristone, a drug approved in 2000 and widely used in medication abortions alongside misoprostol. Drug manufacturers Danco Laboratories and GenBioPro challenged the lower court restrictions after the 5th U.S. Circuit Court of Appeals ordered the reinstatement of older rules requiring in-person dispensing. The case has intensified the national abortion debate following the court’s 2022 Dobbs ruling, which overturned Roe v. Wade and enabled multiple states to impose near-total abortion bans. Anti-abortion advocates argue that mail-order abortion pills undermine state restrictions, while reproductive rights groups maintain that mifepristone is safe, effective, and supported by extensive medical research.
Abortion rights organizations welcomed the Supreme Court’s move, calling it a crucial step in maintaining healthcare access while litigation continues. Planned Parenthood Federation of America president Alexis McGill Johnson described the ruling as a relief for patients nationwide, while medical experts reiterated that mifepristone remains one of the most extensively studied medications in the United States. However, anti-abortion groups criticized the decision, with National Right to Life warning that mail-order abortion access poses risks to women’s health. Additional lawsuits filed by Republican-led states, including Texas and Florida, continue to seek broader restrictions on the abortion pill.
Pic Courtesy: google/ images are subject to copyright
